- Home
- BMBL vs ATXS Comparison
BMBL vs ATXS Comparison
Compare BMBL & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMBL
- ATXS
- Stock Information
- Founded
- BMBL 2014
- ATXS 2008
- Country
- BMBL United States
- ATXS United States
- Employees
- BMBL N/A
- ATXS N/A
- Industry
- BMBL Computer Software: Prepackaged Software
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- BMBL Technology
- ATXS Health Care
- Exchange
- BMBL Nasdaq
- ATXS Nasdaq
- Market Cap
- BMBL 446.5M
- ATXS 401.2M
- IPO Year
- BMBL 2021
- ATXS 2015
- Fundamental
- Price
- BMBL $5.74
- ATXS $4.78
- Analyst Decision
- BMBL Hold
- ATXS Strong Buy
- Analyst Count
- BMBL 15
- ATXS 7
- Target Price
- BMBL $6.56
- ATXS $32.43
- AVG Volume (30 Days)
- BMBL 3.5M
- ATXS 625.9K
- Earning Date
- BMBL 05-07-2025
- ATXS 05-13-2025
- Dividend Yield
- BMBL N/A
- ATXS N/A
- EPS Growth
- BMBL N/A
- ATXS N/A
- EPS
- BMBL N/A
- ATXS N/A
- Revenue
- BMBL $1,050,969,000.00
- ATXS N/A
- Revenue This Year
- BMBL N/A
- ATXS N/A
- Revenue Next Year
- BMBL N/A
- ATXS N/A
- P/E Ratio
- BMBL N/A
- ATXS N/A
- Revenue Growth
- BMBL N/A
- ATXS N/A
- 52 Week Low
- BMBL $3.55
- ATXS $3.56
- 52 Week High
- BMBL $12.03
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- BMBL 57.60
- ATXS 55.21
- Support Level
- BMBL $5.67
- ATXS $3.83
- Resistance Level
- BMBL $6.26
- ATXS $4.98
- Average True Range (ATR)
- BMBL 0.25
- ATXS 0.44
- MACD
- BMBL -0.03
- ATXS 0.12
- Stochastic Oscillator
- BMBL 25.71
- ATXS 84.48
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.